ZUNVEYL demand accelerated: Second-quarter product revenue rose 71% sequentially to approximately $6 million, supported by a 37% increase in bottles sold, broader prescriber adoption and a 20% rise in nursing-home facilities ordering the drug. Payer access remains the main growth constraint: The company's contracted open-book coverage stayed at 16%, limiting broader expansion into retail and neurology channels, although repeat orders and underlying demand remained strong. Evidence programs and finances progressed: Alpha Cognition reported positive top-line BEACON findings, advanced CONVERGE and RESOLVE, held $41.4 million in cash, and lowered 2026 operating-expense guidance to $50 million-$54 million while maintaining a 2027 operating-profitability target.
Alpha Cognition (NASDAQ:ACOG) reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facilities. Total revenue was $6.1 million, compared with $1.7 million in the prior-year period. GAAP gross product margin was approximately 94%, with cost of product sales totaling roughly $0.4 million.
The company recorded a net loss of $8.8 million, or $0.40 per share, improving from a loss of $13.2 million, or $0.82 per share, a year earlier. → AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be "It was a strong quarter of execution with clear sequential growth in ZUNVEYL demand, expansion in prescriber adoption, increased nursing home penetration, and continued progress with evidence generation," Chief Executive Officer Michael McFadden said on the company's Aug. 13 earnings call. Chief Operating Officer Lauren D'Angelo said second-quarter demand included approximately 8,294 bottles of ZUNVEYL, a 37% increase from the prior quarter. The company reached 8,194 total customers and called on 3,905 prescribers through its approximately 60-person field organization. → Nebius' Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Healthcare provider writers—prescribers issuing at least one ZUNVEYL prescription—increased 27% from the first quarter to 1,347.
Cumulative life-to-date writers reached 1,908, nearing the company's approximately 2,000-writer goal for 2026. Among 1,024 second-quarter writers, approximately 76% placed repeat prescriptions, while prescriptions per writer rose to about six, according to D'Angelo. Nursing homes with ZUNVEYL prescriptions increased 20% sequentially to 1,095, including 346 facilities added during the quarter.
About 81% of facilities that ordered the drug placed repeat orders. → On Holding's Price Stumble May Be an Opening for a Company Built to Run D'Angelo said demand increased each month during the quarter, with June representing the strongest month to date. She added that momentum continued into the third quarter, though the company does not provide revenue guidance. Management said growth was not driven by material inventory stocking at wholesalers or pharmacies.
"What you see this quarter is pure demand growth," D'Angelo said, adding that pharmacies and wholesalers are now generally buying on demand. While ZUNVEYL demand grew, the company said broad formulary activation among downstream payer clients did not materialize at the pace management previously expected. D'Angelo described payer access as the company's most significant near-term opportunity and friction point.
Extract — continue reading at the source.
